Targeting Metabolic Vulnerabilities in Myeloid Malignancies

Articles

ORIGINAL RESEARCH

Published on 20 Aug 2021

The Combined Treatment With the FLT3-Inhibitor AC220 and the Complex I Inhibitor IACS-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells

REVIEW

Published on 01 Jul 2021

Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias

ORIGINAL RESEARCH

Published on 10 Jun 2021

Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML

REVIEW

Published on 20 May 2021

Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies

REVIEW

Published on 22 Feb 2021

Clinical Implications of Inflammation in Acute Myeloid Leukemia

ORIGINAL RESEARCH

Published on 05 Feb 2021

Targeting Lactate Metabolism by Inhibiting MCT1 or MCT4 Impairs Leukemic Cell Proliferation, Induces Two Different Related Death-Pathways and Increases Chemotherapeutic Sensitivity of Acute Myeloid Leukemia Cells

Share on

Frontiers in Oncology

Submit your idea

Articles

The Combined Treatment With the FLT3-Inhibitor AC220 and the Complex I Inhibitor IACS-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells

Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias

Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML

Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies

Clinical Implications of Inflammation in Acute Myeloid Leukemia

Targeting Lactate Metabolism by Inhibiting MCT1 or MCT4 Impairs Leukemic Cell Proliferation, Induces Two Different Related Death-Pathways and Increases Chemotherapeutic Sensitivity of Acute Myeloid Leukemia Cells

Frontiers in Oncology